OpGen Submits Updated 510(k) Summary to FDA and Successfully Completes Move to New Headquarters in Maryland
June 07, 2021 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., June 07, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat...
OpGen Reports First Quarter 2021 Financial Results and Provides Business Update
May 13, 2021 07:30 ET
|
OpGen, Inc.
Total Revenue for Q1 2021 was approximately $0.8 millionBalance sheet strengthened significantly with an additional $34.7 million cash raised in Q1 2021 Conference call to be held at 8:30 a.m....
OpGen to Provide Business Update and Financial Results for the First Quarter 2021 on May 13th at 8:30 a.m. Eastern Time
April 29, 2021 07:30 ET
|
OpGen, Inc.
GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first...
OpGen Extends and Expands Partnership with New York State Department of Health to Detect Antimicrobial-Resistant Infections
April 19, 2021 07:30 ET
|
OpGen, Inc.
Collaboration with NYS Department of Health’s Wadsworth Center continues for extended six-month term until September 30, 2021 Project utilizes OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse®...
OpGen Announces Results from Successful Webinar on Bacterial Pneumonia Co-infections in COVID-19 Patients
April 12, 2021 07:30 ET
|
OpGen, Inc.
Experts presented the results of their Unyvero studies and demonstrated: Distinguishing those COVID-19 ICU patients with bacterial superinfection early and accurately is crucial for patient...
OpGen Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 25, 2021 16:01 ET
|
OpGen, Inc.
Total combined pro-forma revenue for 2020 was approximately $5.2 million Maintained strong balance sheet with $13.4 million cash as of December 31, 2020 Raised an additional $34.7 million of capital...
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2020
March 11, 2021 07:30 ET
|
OpGen, Inc.
GAITHERSBURG, Md., March 11, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth...
OpGen Announces Publication of Final Study Results of Unyvero HPN Panel for Diagnosis of Bacterial Co-Infections in ICU Patients with COVID-19 Pneumonia
March 08, 2021 07:30 ET
|
OpGen, Inc.
Karolinska Institutet Study highlights Unyvero HPN demonstrating a higher diagnostic yield than bacterial culture, enabling rapid diagnosis of pathogens of concern in these patients High negative...
OpGen Wins Chinese NMPA Approval for the Curetis Unyvero System
March 01, 2021 07:30 ET
|
OpGen, Inc.
Chinese regulatory authority NMPA completes registration of Unyvero instrument system as IVD for Chinese marketApplication of Unyvero cartridge for pneumonia is under review and pending NMPA...
OpGen Subsidiary Ares Genetics Announces Publication of Study Introducing Best Practice Techniques for AI-powered Prediction of Antibiotic Susceptibility Testing by Next-Generation Sequencing
February 16, 2021 07:30 ET
|
OpGen, Inc.
Study highlights best practice techniques for accurate antimicrobial resistance prediction from whole-genome sequencing data Publication supports harmonization of the development of good machine...